Panjon Pharma Ltd. announced unaudited earnings results for second quarter and six months ended Sept. 30, 2013. For the quarter, the company reported net sales/income from operations of INR 34.485 million, total income from operations of INR 54.485 million, profit from operations before other income, finance costs and exceptional items of INR 0.208 million, profit from ordinary activities before tax of INR 0.202 million, net profit of INR 0.202 million or INR 0.03 per basic and diluted share after extraordinary items compared to the net sales/income from operations of INR 51.121 million, total income from operations of INR 51.121 million, profit from operations before other income, finance costs and exceptional items of INR 0.557 million, profit from ordinary activities before tax of INR 0.462 million, net profit of INR 0.732 million or INR 0.03 per basic and diluted share after extraordinary items for the same quarter a year ago.

For the year to date, the company reported net sales/income from operations of INR 64.084 million, total income from operations of INR 64.084 million, profit from operations before other income, finance costs and exceptional items of INR 0.485 million, profit from ordinary activities before tax of INR 0.739 million, net profit of INR 0.739 million or INR 0.03 per basic and diluted share after extraordinary items compared to the net sales/income from operations of INR 87.591 million, total income from operations of INR 87.591 million, profit from operations before other income, finance costs and exceptional items of INR 0.940 million, profit from ordinary activities before tax of INR 0.715 million, net profit of INR 0.715 million or INR 0.03 per basic and diluted share after extraordinary items for the same period a year ago.